Global Hepatic Encephalopathy Drugs Market Growth 2025-2031

December 2025 | 96 pages | ID: G30A411E1D1EN
LP Information

Abstracts

The global Hepatic Encephalopathy Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Hepatic encephalopathy (HE) is a severe complication of TIPS treatment in patients with cirrhosis and variceal bleeding. Lactulose, is considered the first-line therapeutic agent for treating hepatic encephalopathy. Based on route of administration, Hepatic Encephalopathy Drugs include oral (tablets & solutions) and injections.

United States market for Hepatic Encephalopathy Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Hepatic Encephalopathy Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Hepatic Encephalopathy Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Hepatic Encephalopathy Drugs players cover ASKA Pharmaceutical, Cosmo Pharmaceuticals, Bausch Health, Ferring Pharmaceuticals, Mallinckrodt, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Hepatic Encephalopathy Drugs Industry Forecast” looks at past sales and reviews total world Hepatic Encephalopathy Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Hepatic Encephalopathy Drugs sales for 2025 through 2031. With Hepatic Encephalopathy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatic Encephalopathy Drugs industry.

This Insight Report provides a comprehensive analysis of the global Hepatic Encephalopathy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatic Encephalopathy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hepatic Encephalopathy Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatic Encephalopathy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatic Encephalopathy Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Hepatic Encephalopathy Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Injection
• Oral

Segmentation by Application:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• ASKA Pharmaceutical
• Cosmo Pharmaceuticals
• Bausch Health
• Ferring Pharmaceuticals
• Mallinckrodt
• Umecrine Cognition
• Norgine
• Lupin
• Kaleido Biosciences
• Kannalife Sciences

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hepatic Encephalopathy Drugs market?

What factors are driving Hepatic Encephalopathy Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Hepatic Encephalopathy Drugs market opportunities vary by end market size?

How does Hepatic Encephalopathy Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Hepatic Encephalopathy Drugs Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Hepatic Encephalopathy Drugs by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Hepatic Encephalopathy Drugs by Country/Region, 2020, 2024 & 2031
2.2 Hepatic Encephalopathy Drugs Segment by Type
  2.2.1 Injection
  2.2.2 Oral
2.3 Hepatic Encephalopathy Drugs Sales by Type
  2.3.1 Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2020-2025)
  2.3.2 Global Hepatic Encephalopathy Drugs Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Hepatic Encephalopathy Drugs Sale Price by Type (2020-2025)
2.4 Hepatic Encephalopathy Drugs Segment by Application
  2.4.1 Hospital Pharmacies
  2.4.2 Retail Pharmacies
  2.4.3 Online Pharmacies
2.5 Hepatic Encephalopathy Drugs Sales by Application
  2.5.1 Global Hepatic Encephalopathy Drugs Sale Market Share by Application (2020-2025)
  2.5.2 Global Hepatic Encephalopathy Drugs Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Hepatic Encephalopathy Drugs Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Hepatic Encephalopathy Drugs Breakdown Data by Company
  3.1.1 Global Hepatic Encephalopathy Drugs Annual Sales by Company (2020-2025)
  3.1.2 Global Hepatic Encephalopathy Drugs Sales Market Share by Company (2020-2025)
3.2 Global Hepatic Encephalopathy Drugs Annual Revenue by Company (2020-2025)
  3.2.1 Global Hepatic Encephalopathy Drugs Revenue by Company (2020-2025)
  3.2.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Hepatic Encephalopathy Drugs Sale Price by Company
3.4 Key Manufacturers Hepatic Encephalopathy Drugs Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Hepatic Encephalopathy Drugs Product Location Distribution
  3.4.2 Players Hepatic Encephalopathy Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR HEPATIC ENCEPHALOPATHY DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Hepatic Encephalopathy Drugs Market Size by Geographic Region (2020-2025)
  4.1.1 Global Hepatic Encephalopathy Drugs Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Hepatic Encephalopathy Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Hepatic Encephalopathy Drugs Market Size by Country/Region (2020-2025)
  4.2.1 Global Hepatic Encephalopathy Drugs Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Hepatic Encephalopathy Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Hepatic Encephalopathy Drugs Sales Growth
4.4 APAC Hepatic Encephalopathy Drugs Sales Growth
4.5 Europe Hepatic Encephalopathy Drugs Sales Growth
4.6 Middle East & Africa Hepatic Encephalopathy Drugs Sales Growth

5 AMERICAS

5.1 Americas Hepatic Encephalopathy Drugs Sales by Country
  5.1.1 Americas Hepatic Encephalopathy Drugs Sales by Country (2020-2025)
  5.1.2 Americas Hepatic Encephalopathy Drugs Revenue by Country (2020-2025)
5.2 Americas Hepatic Encephalopathy Drugs Sales by Type (2020-2025)
5.3 Americas Hepatic Encephalopathy Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Hepatic Encephalopathy Drugs Sales by Region
  6.1.1 APAC Hepatic Encephalopathy Drugs Sales by Region (2020-2025)
  6.1.2 APAC Hepatic Encephalopathy Drugs Revenue by Region (2020-2025)
6.2 APAC Hepatic Encephalopathy Drugs Sales by Type (2020-2025)
6.3 APAC Hepatic Encephalopathy Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Hepatic Encephalopathy Drugs by Country
  7.1.1 Europe Hepatic Encephalopathy Drugs Sales by Country (2020-2025)
  7.1.2 Europe Hepatic Encephalopathy Drugs Revenue by Country (2020-2025)
7.2 Europe Hepatic Encephalopathy Drugs Sales by Type (2020-2025)
7.3 Europe Hepatic Encephalopathy Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Hepatic Encephalopathy Drugs by Country
  8.1.1 Middle East & Africa Hepatic Encephalopathy Drugs Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Hepatic Encephalopathy Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Hepatic Encephalopathy Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Hepatic Encephalopathy Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hepatic Encephalopathy Drugs
10.3 Manufacturing Process Analysis of Hepatic Encephalopathy Drugs
10.4 Industry Chain Structure of Hepatic Encephalopathy Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Hepatic Encephalopathy Drugs Distributors
11.3 Hepatic Encephalopathy Drugs Customer

12 WORLD FORECAST REVIEW FOR HEPATIC ENCEPHALOPATHY DRUGS BY GEOGRAPHIC REGION

12.1 Global Hepatic Encephalopathy Drugs Market Size Forecast by Region
  12.1.1 Global Hepatic Encephalopathy Drugs Forecast by Region (2026-2031)
  12.1.2 Global Hepatic Encephalopathy Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Hepatic Encephalopathy Drugs Forecast by Type (2026-2031)
12.7 Global Hepatic Encephalopathy Drugs Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 ASKA Pharmaceutical
  13.1.1 ASKA Pharmaceutical Company Information
  13.1.2 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.1.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 ASKA Pharmaceutical Main Business Overview
  13.1.5 ASKA Pharmaceutical Latest Developments
13.2 Cosmo Pharmaceuticals
  13.2.1 Cosmo Pharmaceuticals Company Information
  13.2.2 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.2.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Cosmo Pharmaceuticals Main Business Overview
  13.2.5 Cosmo Pharmaceuticals Latest Developments
13.3 Bausch Health
  13.3.1 Bausch Health Company Information
  13.3.2 Bausch Health Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.3.3 Bausch Health Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Bausch Health Main Business Overview
  13.3.5 Bausch Health Latest Developments
13.4 Ferring Pharmaceuticals
  13.4.1 Ferring Pharmaceuticals Company Information
  13.4.2 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.4.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Ferring Pharmaceuticals Main Business Overview
  13.4.5 Ferring Pharmaceuticals Latest Developments
13.5 Mallinckrodt
  13.5.1 Mallinckrodt Company Information
  13.5.2 Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.5.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Mallinckrodt Main Business Overview
  13.5.5 Mallinckrodt Latest Developments
13.6 Umecrine Cognition
  13.6.1 Umecrine Cognition Company Information
  13.6.2 Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.6.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Umecrine Cognition Main Business Overview
  13.6.5 Umecrine Cognition Latest Developments
13.7 Norgine
  13.7.1 Norgine Company Information
  13.7.2 Norgine Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.7.3 Norgine Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Norgine Main Business Overview
  13.7.5 Norgine Latest Developments
13.8 Lupin
  13.8.1 Lupin Company Information
  13.8.2 Lupin Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.8.3 Lupin Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Lupin Main Business Overview
  13.8.5 Lupin Latest Developments
13.9 Kaleido Biosciences
  13.9.1 Kaleido Biosciences Company Information
  13.9.2 Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.9.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Kaleido Biosciences Main Business Overview
  13.9.5 Kaleido Biosciences Latest Developments
13.10 Kannalife Sciences
  13.10.1 Kannalife Sciences Company Information
  13.10.2 Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolios and Specifications
  13.10.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.10.4 Kannalife Sciences Main Business Overview
  13.10.5 Kannalife Sciences Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Hepatic Encephalopathy Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Hepatic Encephalopathy Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Injection
Table 4. Major Players of Oral
Table 5. Global Hepatic Encephalopathy Drugs Sales by Type (2020-2025) & (MT)
Table 6. Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2020-2025)
Table 7. Global Hepatic Encephalopathy Drugs Revenue by Type (2020-2025) & ($ million)
Table 8. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2020-2025)
Table 9. Global Hepatic Encephalopathy Drugs Sale Price by Type (2020-2025) & (USD/Kg)
Table 10. Global Hepatic Encephalopathy Drugs Sale by Application (2020-2025) & (MT)
Table 11. Global Hepatic Encephalopathy Drugs Sale Market Share by Application (2020-2025)
Table 12. Global Hepatic Encephalopathy Drugs Revenue by Application (2020-2025) & ($ million)
Table 13. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2020-2025)
Table 14. Global Hepatic Encephalopathy Drugs Sale Price by Application (2020-2025) & (USD/Kg)
Table 15. Global Hepatic Encephalopathy Drugs Sales by Company (2020-2025) & (MT)
Table 16. Global Hepatic Encephalopathy Drugs Sales Market Share by Company (2020-2025)
Table 17. Global Hepatic Encephalopathy Drugs Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Hepatic Encephalopathy Drugs Revenue Market Share by Company (2020-2025)
Table 19. Global Hepatic Encephalopathy Drugs Sale Price by Company (2020-2025) & (USD/Kg)
Table 20. Key Manufacturers Hepatic Encephalopathy Drugs Producing Area Distribution and Sales Area
Table 21. Players Hepatic Encephalopathy Drugs Products Offered
Table 22. Hepatic Encephalopathy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Hepatic Encephalopathy Drugs Sales by Geographic Region (2020-2025) & (MT)
Table 26. Global Hepatic Encephalopathy Drugs Sales Market Share Geographic Region (2020-2025)
Table 27. Global Hepatic Encephalopathy Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Hepatic Encephalopathy Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Hepatic Encephalopathy Drugs Sales by Country/Region (2020-2025) & (MT)
Table 30. Global Hepatic Encephalopathy Drugs Sales Market Share by Country/Region (2020-2025)
Table 31. Global Hepatic Encephalopathy Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Hepatic Encephalopathy Drugs Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Hepatic Encephalopathy Drugs Sales by Country (2020-2025) & (MT)
Table 34. Americas Hepatic Encephalopathy Drugs Sales Market Share by Country (2020-2025)
Table 35. Americas Hepatic Encephalopathy Drugs Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Hepatic Encephalopathy Drugs Sales by Type (2020-2025) & (MT)
Table 37. Americas Hepatic Encephalopathy Drugs Sales by Application (2020-2025) & (MT)
Table 38. APAC Hepatic Encephalopathy Drugs Sales by Region (2020-2025) & (MT)
Table 39. APAC Hepatic Encephalopathy Drugs Sales Market Share by Region (2020-2025)
Table 40. APAC Hepatic Encephalopathy Drugs Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Hepatic Encephalopathy Drugs Sales by Type (2020-2025) & (MT)
Table 42. APAC Hepatic Encephalopathy Drugs Sales by Application (2020-2025) & (MT)
Table 43. Europe Hepatic Encephalopathy Drugs Sales by Country (2020-2025) & (MT)
Table 44. Europe Hepatic Encephalopathy Drugs Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Hepatic Encephalopathy Drugs Sales by Type (2020-2025) & (MT)
Table 46. Europe Hepatic Encephalopathy Drugs Sales by Application (2020-2025) & (MT)
Table 47. Middle East & Africa Hepatic Encephalopathy Drugs Sales by Country (2020-2025) & (MT)
Table 48. Middle East & Africa Hepatic Encephalopathy Drugs Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Hepatic Encephalopathy Drugs Sales by Type (2020-2025) & (MT)
Table 50. Middle East & Africa Hepatic Encephalopathy Drugs Sales by Application (2020-2025) & (MT)
Table 51. Key Market Drivers & Growth Opportunities of Hepatic Encephalopathy Drugs
Table 52. Key Market Challenges & Risks of Hepatic Encephalopathy Drugs
Table 53. Key Industry Trends of Hepatic Encephalopathy Drugs
Table 54. Hepatic Encephalopathy Drugs Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Hepatic Encephalopathy Drugs Distributors List
Table 57. Hepatic Encephalopathy Drugs Customer List
Table 58. Global Hepatic Encephalopathy Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 59. Global Hepatic Encephalopathy Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Hepatic Encephalopathy Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 61. Americas Hepatic Encephalopathy Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Hepatic Encephalopathy Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 63. APAC Hepatic Encephalopathy Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Hepatic Encephalopathy Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 65. Europe Hepatic Encephalopathy Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Hepatic Encephalopathy Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 67. Middle East & Africa Hepatic Encephalopathy Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Hepatic Encephalopathy Drugs Sales Forecast by Type (2026-2031) & (MT)
Table 69. Global Hepatic Encephalopathy Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Hepatic Encephalopathy Drugs Sales Forecast by Application (2026-2031) & (MT)
Table 71. Global Hepatic Encephalopathy Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. ASKA Pharmaceutical Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 74. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 75. ASKA Pharmaceutical Main Business
Table 76. ASKA Pharmaceutical Latest Developments
Table 77. Cosmo Pharmaceuticals Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 79. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 80. Cosmo Pharmaceuticals Main Business
Table 81. Cosmo Pharmaceuticals Latest Developments
Table 82. Bausch Health Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Bausch Health Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 84. Bausch Health Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 85. Bausch Health Main Business
Table 86. Bausch Health Latest Developments
Table 87. Ferring Pharmaceuticals Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 89. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 90. Ferring Pharmaceuticals Main Business
Table 91. Ferring Pharmaceuticals Latest Developments
Table 92. Mallinckrodt Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 94. Mallinckrodt Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 95. Mallinckrodt Main Business
Table 96. Mallinckrodt Latest Developments
Table 97. Umecrine Cognition Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 99. Umecrine Cognition Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 100. Umecrine Cognition Main Business
Table 101. Umecrine Cognition Latest Developments
Table 102. Norgine Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Norgine Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 104. Norgine Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 105. Norgine Main Business
Table 106. Norgine Latest Developments
Table 107. Lupin Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Lupin Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 109. Lupin Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 110. Lupin Main Business
Table 111. Lupin Latest Developments
Table 112. Kaleido Biosciences Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 114. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 115. Kaleido Biosciences Main Business
Table 116. Kaleido Biosciences Latest Developments
Table 117. Kannalife Sciences Basic Information, Hepatic Encephalopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolios and Specifications
Table 119. Kannalife Sciences Hepatic Encephalopathy Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 120. Kannalife Sciences Main Business
Table 121. Kannalife Sciences Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Hepatic Encephalopathy Drugs
Figure 2. Hepatic Encephalopathy Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Hepatic Encephalopathy Drugs Sales Growth Rate 2020-2031 (MT)
Figure 7. Global Hepatic Encephalopathy Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Hepatic Encephalopathy Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Hepatic Encephalopathy Drugs Sales Market Share by Country/Region (2024)
Figure 10. Hepatic Encephalopathy Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Injection
Figure 12. Product Picture of Oral
Figure 13. Global Hepatic Encephalopathy Drugs Sales Market Share by Type in 2025
Figure 14. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2020-2025)
Figure 15. Hepatic Encephalopathy Drugs Consumed in Hospital Pharmacies
Figure 16. Global Hepatic Encephalopathy Drugs Market: Hospital Pharmacies (2020-2025) & (MT)
Figure 17. Hepatic Encephalopathy Drugs Consumed in Retail Pharmacies
Figure 18. Global Hepatic Encephalopathy Drugs Market: Retail Pharmacies (2020-2025) & (MT)
Figure 19. Hepatic Encephalopathy Drugs Consumed in Online Pharmacies
Figure 20. Global Hepatic Encephalopathy Drugs Market: Online Pharmacies (2020-2025) & (MT)
Figure 21. Global Hepatic Encephalopathy Drugs Sale Market Share by Application (2024)
Figure 22. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application in 2025
Figure 23. Hepatic Encephalopathy Drugs Sales by Company in 2025 (MT)
Figure 24. Global Hepatic Encephalopathy Drugs Sales Market Share by Company in 2025
Figure 25. Hepatic Encephalopathy Drugs Revenue by Company in 2025 ($ millions)
Figure 26. Global Hepatic Encephalopathy Drugs Revenue Market Share by Company in 2025
Figure 27. Global Hepatic Encephalopathy Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 28. Global Hepatic Encephalopathy Drugs Revenue Market Share by Geographic Region in 2025
Figure 29. Americas Hepatic Encephalopathy Drugs Sales 2020-2025 (MT)
Figure 30. Americas Hepatic Encephalopathy Drugs Revenue 2020-2025 ($ millions)
Figure 31. APAC Hepatic Encephalopathy Drugs Sales 2020-2025 (MT)
Figure 32. APAC Hepatic Encephalopathy Drugs Revenue 2020-2025 ($ millions)
Figure 33. Europe Hepatic Encephalopathy Drugs Sales 2020-2025 (MT)
Figure 34. Europe Hepatic Encephalopathy Drugs Revenue 2020-2025 ($ millions)
Figure 35. Middle East & Africa Hepatic Encephalopathy Drugs Sales 2020-2025 (MT)
Figure 36. Middle East & Africa Hepatic Encephalopathy Drugs Revenue 2020-2025 ($ millions)
Figure 37. Americas Hepatic Encephalopathy Drugs Sales Market Share by Country in 2025
Figure 38. Americas Hepatic Encephalopathy Drugs Revenue Market Share by Country (2020-2025)
Figure 39. Americas Hepatic Encephalopathy Drugs Sales Market Share by Type (2020-2025)
Figure 40. Americas Hepatic Encephalopathy Drugs Sales Market Share by Application (2020-2025)
Figure 41. United States Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 42. Canada Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Mexico Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Brazil Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. APAC Hepatic Encephalopathy Drugs Sales Market Share by Region in 2025
Figure 46. APAC Hepatic Encephalopathy Drugs Revenue Market Share by Region (2020-2025)
Figure 47. APAC Hepatic Encephalopathy Drugs Sales Market Share by Type (2020-2025)
Figure 48. APAC Hepatic Encephalopathy Drugs Sales Market Share by Application (2020-2025)
Figure 49. China Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 50. Japan Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. South Korea Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. Southeast Asia Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. India Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. Australia Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. China Taiwan Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. Europe Hepatic Encephalopathy Drugs Sales Market Share by Country in 2025
Figure 57. Europe Hepatic Encephalopathy Drugs Revenue Market Share by Country (2020-2025)
Figure 58. Europe Hepatic Encephalopathy Drugs Sales Market Share by Type (2020-2025)
Figure 59. Europe Hepatic Encephalopathy Drugs Sales Market Share by Application (2020-2025)
Figure 60. Germany Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 61. France Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. UK Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. Italy Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Russia Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Middle East & Africa Hepatic Encephalopathy Drugs Sales Market Share by Country (2020-2025)
Figure 66. Middle East & Africa Hepatic Encephalopathy Drugs Sales Market Share by Type (2020-2025)
Figure 67. Middle East & Africa Hepatic Encephalopathy Drugs Sales Market Share by Application (2020-2025)
Figure 68. Egypt Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 69. South Africa Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. Israel Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. Turkey Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. GCC Countries Hepatic Encephalopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Hepatic Encephalopathy Drugs in 2025
Figure 74. Manufacturing Process Analysis of Hepatic Encephalopathy Drugs
Figure 75. Industry Chain Structure of Hepatic Encephalopathy Drugs
Figure 76. Channels of Distribution
Figure 77. Global Hepatic Encephalopathy Drugs Sales Market Forecast by Region (2026-2031)
Figure 78. Global Hepatic Encephalopathy Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 79. Global Hepatic Encephalopathy Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 80. Global Hepatic Encephalopathy Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 81. Global Hepatic Encephalopathy Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 82. Global Hepatic Encephalopathy Drugs Revenue Market Share Forecast by Application (2026-2031)